Covagen

Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins with antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy for treating inflammatory diseases and cancer. Their aim is to unlock new biology for each candidate product. Covagen's leading product, FynomAb COVA322, is under development for the treatment of inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis.